Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

NETWORK

Sponsor class

Conditions

Central Nervous System Neoplasm
Infantile Fibrosarcoma
Recurrent Acute Leukemia
Refractory Acute Leukemia
Solid Neoplasm

Interventions

DRUG: Larotrectinib Sulfate

Sponsor

Children's Oncology Group

Collaborators

[object Object]